Evogene Ltd. (EVGN) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Evogene Ltd. (EVGN) Healthcare & Pipeline Overview

Evogene Ltd. is a computational biology company leveraging its proprietary CPB platform to discover and develop products in agriculture, human health, and industrial applications. With strategic collaborations and a focus on innovative solutions, Evogene aims to enhance plant performance, develop microbiome-based therapeutics, and create sustainable industrial feedstocks.

What Is the Investment Thesis for EVGN?

Evogene presents a high-risk, high-reward investment opportunity within the computational biology sector. The company's CPB platform offers potential for significant breakthroughs in agriculture, human health, and industrial applications. However, with a negative profit margin of -639.4%, the company's financial stability is a concern. Key value drivers include successful commercialization of products developed through the CPB platform and continued strategic collaborations with industry leaders. Growth catalysts include advancements in microbiome-based therapeutics and the expansion of its agricultural product portfolio. Potential risks include the inherent uncertainty of drug development, regulatory hurdles, and competition from established players in the biotechnology and agricultural sectors. Investors should closely monitor the company's progress in achieving profitability and securing additional funding to support its research and development efforts.

Based on FMP financials and quantitative analysis

EVGN Key Highlights

Evogene operates in three segments: Agriculture, Human Health, and Industrial Applications, diversifying its revenue streams and mitigating risk.

• The company's Computational Predictive Biology (CPB) platform leverages big data and AI to accelerate product discovery and development.
• Strategic collaborations with industry giants like BASF SE, Corteva, and Bayer provide validation and access to resources.
• Evogene's gross margin of 30.9% indicates potential for profitability if operating expenses are managed effectively.
• The company's focus on microbiome-based therapeutics positions it in a high-growth area of the healthcare sector.

Who Are EVGN's Competitors?

EVGN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are EVGN's Key Strengths?

Proprietary Computational Predictive Biology (CPB) platform

• Strategic collaborations with industry leaders
• Diversified product portfolio across multiple sectors
• Focus on innovative and sustainable solutions

What Are EVGN's Weaknesses?

Negative profit margin

• High R&D costs
• Dependence on strategic collaborations
• Limited commercialized products

What Could Drive EVGN Stock Higher?

Clinical trial results for microbiome-based therapeutics in immuno-oncology.

• Expansion of strategic collaborations with agricultural companies.
• Advancements in the development of enhanced castor bean seeds for industrial uses.
• Regulatory approvals for new agricultural products.

What Are the Key Risks for EVGN?

Financial-distress signal — its Altman Z-Score of -32.42 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in clinical trials.
• Competition from established players in the biotechnology and agricultural sectors.
• High R&D costs and the need for additional funding.
• Regulatory hurdles and delays in product approvals.
• Dependence on strategic collaborations for product development and commercialization.

What Are the Growth Opportunities for EVGN?

• Expansion in Microbiome-Based Therapeutics: The human microbiome market is projected to reach $1.6 billion by 2027, presenting a significant opportunity for Evogene's Human Health segment. Evogene can capitalize on this growth by advancing its pipeline of microbiome-based therapeutics for immuno-oncology, GI-related disorders, and antimicrobial resistance. Success in clinical trials and regulatory approvals will be critical for realizing this potential.
• Advancements in Agricultural Products: The agricultural biotechnology market is expected to reach $62.3 billion by 2027, driven by the need for enhanced crop yields and sustainable farming practices. Evogene can leverage its CPB platform to develop innovative seed traits, ag-chemical products, and ag-biological products that improve plant performance and reduce environmental impact. Strategic partnerships with agricultural companies will be essential for market penetration.
• Development of Industrial Applications: The market for sustainable industrial feedstocks is growing as companies seek to reduce their reliance on fossil fuels. Evogene's Industrial Applications segment can capitalize on this trend by developing enhanced castor bean seeds that serve as a sustainable feedstock source for various industrial uses. Collaborations with industrial partners will be crucial for scaling up production and commercialization.
• Strategic Collaborations and Licensing Agreements: Evogene's existing collaborations with BASF SE, Corteva, and Bayer provide access to resources, expertise, and market channels. The company can further expand its network of strategic partners to accelerate product development and commercialization. Licensing agreements for its proprietary technologies can also generate revenue and expand its market reach.
• Geographic Expansion: Evogene currently operates in the United States, Israel, Brazil, and other international markets. The company can further expand its geographic footprint by targeting high-growth markets in Asia and Latin America. Adapting its products and services to meet the specific needs of these markets will be essential for success.

What Are EVGN's Competitive Advantages?

• Proprietary Computational Predictive Biology (CPB) platform provides a competitive advantage in product discovery and development.
• Strategic collaborations with industry leaders enhance credibility and access to resources.
• Diversified product portfolio across agriculture, human health, and industrial applications reduces risk.

What Does EVGN Do?

Founded in 1999 and headquartered in Rehovot, Israel, Evogene Ltd. operates as a computational biology company, pioneering the use of its Computational Predictive Biology (CPB) platform to drive product discovery and development across multiple life-science industries. The company's CPB platform integrates a deep understanding of biology with big data and artificial intelligence, enabling the computational discovery and development of life-science products based on microbes, small molecules, and genetic elements. Evogene operates through three primary segments: Agriculture, Human Health, and Industrial Applications. In the Agriculture segment, Evogene focuses on developing seed traits, ag-chemical products, and ag-biological products designed to enhance plant performance across a range of crops, including corn, soybean, wheat, rice, and cotton. The Human Health segment is dedicated to discovering and developing human microbiome-based therapeutics for the treatment of immuno-oncology, GI-related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for various industrial uses. Evogene has established strategic collaborations and licensing agreements with leading agricultural companies, including BASF SE, Corteva, and Bayer. Through its subsidiary, Canonic Ltd., Evogene also has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene's global operations extend across the United States, Israel, Brazil, and other international markets, reflecting its commitment to addressing challenges and opportunities in diverse sectors and regions.

What Products and Services Does EVGN Offer?

• Utilize a Computational Predictive Biology (CPB) platform to discover and develop life-science products.
• Develop seed traits, ag-chemical products, and ag-biological products to enhance plant performance.
• Focus on crops such as corn, soybean, wheat, rice, and cotton.
• Develop human microbiome-based therapeutics for immuno-oncology, GI-related disorders, and antimicrobial resistance.
• Develop enhanced castor bean seeds for industrial uses.
• Provide medical cannabis products through its subsidiary, Canonic Ltd.

How Does EVGN Make Money?

• Develop and commercialize products in agriculture, human health, and industrial applications.
• Generate revenue through product sales, licensing agreements, and strategic collaborations.
• Invest heavily in research and development to drive innovation and product discovery.

What Industry Does EVGN Operate In?

Evogene operates within the biotechnology industry, which is characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. The market for computational biology is expanding as companies seek to accelerate drug discovery and development processes. Evogene's focus on microbiome-based therapeutics aligns with growing interest in the human microbiome's role in health and disease. The agricultural biotechnology market is also experiencing growth, driven by the need for sustainable and efficient crop production. Evogene competes with other biotechnology companies, as well as larger agricultural and pharmaceutical firms.

Who Are EVGN's Key Customers?

• Agricultural companies seeking to improve crop yields and sustainability.
• Pharmaceutical companies developing new therapies for human diseases.
• Industrial companies seeking sustainable feedstocks for their operations.

Over the past six months, Evogene Ltd. insiders filed 3 SEC Form 4 transactions — 0 sales and 3 purchases. On net that is roughly 1.3M shares acquired (about $693K) — insiders putting money in tends to read as conviction.

Evogene Ltd. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 13.1% below estimates on average.

Evogene Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -32.42 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -68.2%, showing how much profit it generates from its asset base. A current ratio of 3.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -133.1%, the inverse of the P/E and a quick read on earnings relative to price.

Evogene Ltd. (EVGN) Valuation Context

Valued at $4.14M, EVGN is classified as a micro-cap stock. Analyst price targets span from $2.15 to $2.15, with a consensus of $2.15. At the current price of $0.48, that implies approximately 347% upside potential. Relative to its peer group, EVGN's quantitative score of 19/100 is below the peer average of 67/100.

EVGN Revenue & Earnings Trend

In Q2 FY2026, EVGN generated $347K in top-line revenue, marking a sequential increase of 3.9%. The company recorded a net loss of $1.8M, with diluted EPS of $-0.14. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, EVGN averaged $-0.23 in diluted EPS.

Company Profile

Evogene Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Rehovot, IL. The company is led by CEO Ofer Haviv. EVGN has traded publicly since 2010.

EVGN Financials

EVGN Latest News

EVGN Analyst Consensus

EVGN MoonshotScore

Common Questions About EVGN (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources